BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive: In these experiments, IFN‐G augmented the expression of PD‐L1 on CML LSC which confirmed previous data published by Hogg et al.54We also found that JQ1 and the other BRD4‐targeting drugs tested, including the BRD4 degraders dBET1 and dBET6, inhibit IFN‐G‐induced upregulation of this checkpoint‐target in CML LSC.